Skip to main content

Systemic Juvenile Idiopathic Arthritis

8
Pipeline Programs
6
Companies
11
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
6
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
583%
Small Molecule
117%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
ILARISApproved
canakinumab
Novartis
subcutaneous2009
39M Part D

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
CanakinumabPHASE_3Monoclonal Antibody
Sandoz
SandozAustria - Kundl
5 programs
5
ACZ885Phase 31 trial
CanakinumabPhase 3Monoclonal Antibody1 trial
CanakinumabPhase 3Monoclonal Antibody1 trial
CanakinumabPhase 3Monoclonal Antibody1 trial
canakinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01676948Withdrawn0Est. Jan 2015
NCT00891046Completed270Est. Dec 2014
NCT00886769Terminated84Est. Jan 2011
+2 more trials
Prevail Therapeutics
1 program
1
BaricitinibPhase 3Small Molecule1 trial
Active Trials
NCT04088396Recruiting58Est. Sep 2026
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
SSGJ-613Phase 11 trial
Active Trials
NCT05027373Unknown34Est. Sep 2022
Chugai Pharma
Chugai PharmaJapan - Tokyo
3 programs
MRAPHASE_31 trial
MRAPHASE_31 trial
MRAPHASE_31 trial
Active Trials
NCT00144612Completed60Est. Jun 2009
NCT00144599Completed56Est. Oct 2005
NCT00144664Completed19Est. Oct 2005
Regeneron
RegeneronTARRYTOWN, NY
1 program
rilonaceptPHASE_11 trial
Active Trials
NCT01803321Completed24Est. Jun 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Prevail TherapeuticsBaricitinib
SandozCanakinumab
Sandozcanakinumab
SandozACZ885
SandozCanakinumab
SandozCanakinumab
Chugai PharmaMRA
Chugai PharmaMRA
Chugai PharmaMRA
Sunshine BiopharmaSSGJ-613
Regeneronrilonacept

Clinical Trials (11)

Total enrollment: 655 patients across 11 trials

NCT04088396Prevail TherapeuticsBaricitinib

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: Feb 2020Est. completion: Sep 202658 patients
Phase 3Recruiting
NCT02396212SandozCanakinumab

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Start: May 2015Est. completion: Aug 201819 patients
Phase 3Completed
NCT02334748Sandozcanakinumab

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Start: Nov 2014Est. completion: Aug 201831 patients
Phase 3Completed
NCT01676948SandozACZ885

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Start: Jan 2013Est. completion: Jan 20150
Phase 3Withdrawn
NCT00891046SandozCanakinumab

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

Start: Sep 2009Est. completion: Dec 2014270 patients
Phase 3Completed
NCT00886769SandozCanakinumab

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Start: Jul 2009Est. completion: Jan 201184 patients
Phase 3Terminated
NCT00144664Chugai PharmaMRA

Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Start: Nov 2004Est. completion: Oct 200519 patients
Phase 3Completed
NCT00144612Chugai PharmaMRA

Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: Jul 2004Est. completion: Jun 200960 patients
Phase 3Completed
NCT00144599Chugai PharmaMRA

Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Start: May 2004Est. completion: Oct 200556 patients
Phase 3Completed
NCT05027373Sunshine BiopharmaSSGJ-613

Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection

Start: Aug 2021Est. completion: Sep 202234 patients
Phase 1Unknown
NCT01803321Regeneronrilonacept

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Start: Nov 2005Est. completion: Jun 200824 patients
Phase 1Completed

Related Jobs

Sr. Scientist - T-Cell Therapy Immunology

RegeneronRegeneron
Cambridge
2w ago
$110K - $179K/yr

Country Manager Immunology Spain

RegeneronRegeneron
Madrid
2w ago

Country Manager Immunology DACH (f/m/d)

RegeneronRegeneron
Munich
3w ago

Manager, Regulatory Affairs Strategy - Immunology & Inflammation

RegeneronRegeneron
TARRYTOWN; Warren
1mo ago
$129K - $210K/yr

Medical Specialist I - Allergy-ENT - Salt Lake City N, UT

RegeneronRegeneron
Remote
1mo ago
$144K - $188K/yr

Manager Meetings and Conventions

RegeneronRegeneron
Uxbridge1; Dublin; Madrid; Munich; Milan (Hybrid)
1mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 655 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.